10 of the ETFs we track hold Regeneron Pharmaceuticals Inc in their latest SEC N-PORT filings — ranked by each fund’s portfolio weight in the name.
By portfolio weight, as of each fund’s latest public N-PORT.
| ETF | Weight in REGN | Value | As of |
|---|---|---|---|
| IBB | 7.21% | $586M | 2026-03-31 |
| XLV | 1.47% | $567M | 2026-03-31 |
| XBI | 1.14% | $84.5M | 2026-03-31 |
| QQQ | 0.45% | $1.69B | 2026-03-31 |
| VTV | 0.33% | $742M | 2026-03-31 |
| IWD | 0.26% | $180M | 2026-03-31 |
| SPY | 0.14% | $910M | 2026-03-31 |
| VOO | 0.14% | $1.98B | 2026-03-31 |
| IVV | 0.14% | $1.00B | 2026-03-31 |
| VTI | 0.13% | $2.55B | 2026-03-31 |
Want the other side? See the full book of any fund above on the ETF holdings directory, or go back to REGN’s full analysis.
Source: SEC Form N-PORT-P — each fund’s latest public fiscal-quarter-end report, filed ~2 months after the period. Weight is the ETF’s percent of assets in REGN; value is as reported in the filing. A delayed, roughly quarterly snapshot, not a live position. Covers only the large/liquid ETFs we track, and only holdings that resolve to a ticker — a fund missing here may still hold REGN. No market-price data is used.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.